Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 11/1/2002


1.		Phase I/II Study of Intracranial Iodine I 131 Labeled Anti-Tenascin Monoclonal Antibody 81C6 in Patients With Primary or Metastatic Malignant Anaplastic Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				3 and over								DUMC-2426-01-2R8 DUMC-000223-00-2R7, DUMC-0328-99-2R6, DUMC-221-96-2R3, DUMC-307-97-2R4, DUMC-307-98-2R5, NCI-H96-0009, NCT00002752

Last Modified: 7/1/2000


2.		Phase I/II Study of Intracystic Administration of 131I-Labeled Anti-Tenascin Monoclonal Antibody 81C6 for Patients With Recurrent Cystic Gliomas (Summary Last Modified 07/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				3 and over								DUMC-1965-98-12R7 DUMC-1752-96-12R5, DUMC-1775-95-12R4, DUMC-1860-97-12R6, NCI-H96-0008, NCT00002753

Last Modified: 5/21/2007 First Published: 9/1/1998


3.		Phase I/II Randomized Study of Intratumoral Radiolabeled Antitenascin Monoclonal Antibody 81C6 in Patients With Newly Diagnosed or Recurrent Malignant Primary Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				DUMC-1529-01-8R4 DUMC-1363-97-9, DUMC-1409-98-9R1, DUMC-1529-00-8R3, DUMC-1630-99-9R2, DUMC-97112, NCI-5950NS20023, NCI-G98-1471, NCT00003478

Last Modified: 12/1/2002 First Published: 9/1/1998


4.		Phase I/II Study of Iodine I 131 Antitenascin Monoclonal Antibody 81C6 via Surgically Created Cystic Resection Cavity after Radiotherapy in Patients With Primary Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				DUMC-1533-02-8R5ER DUMC-1533-01-8R4, DUMC-1373-97-9, DUMC-1408-98-9R1, DUMC-1533-00-8R3, DUMC-1570-99-9R2, DUMC-97107, NCI-5P0NS20023, NCI-G98-1472, NCT00003484

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute